United Therapeutics Corporation $UTHR Position Increased by Meeder Asset Management Inc.

Meeder Asset Management Inc. increased its holdings in United Therapeutics Corporation (NASDAQ:UTHR – Free Report) by 37.7% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 12,714 shares of the biotechnology company’s stock after purchasing an additional 3,478 shares during the period. Meeder Asset Management Inc.’s holdings in United Therapeutics were worth $6,890,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in UTHR. Abacus Wealth Partners LLC increased its position in United Therapeutics by 5.6% in the third quarter. Abacus Wealth Partners LLC now owns 396 shares of the biotechnology company’s stock worth $215,000 after purchasing an additional 21 shares during the period. Parallel Advisors LLC increased its position in shares of United Therapeutics by 2.1% in the third quarter. Parallel Advisors LLC now owns 1,154 shares of the biotechnology company’s stock valued at $625,000 after acquiring an additional 24 shares during the last quarter. Meeder Advisory Services Inc. raised its holdings in United Therapeutics by 4.1% during the first quarter. Meeder Advisory Services Inc. now owns 661 shares of the biotechnology company’s stock worth $392,000 after acquiring an additional 26 shares in the last quarter. Florida Financial Advisors LLC increased its position in shares of United Therapeutics by 5.1% during the 1st quarter. Florida Financial Advisors LLC now owns 578 shares of the biotechnology company’s stock worth $343,000 after purchasing an additional 28 shares during the last quarter. Finally, Sumitomo Mitsui DS Asset Management Company Ltd boosted its holdings in shares of United Therapeutics by 0.6% in the 3rd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 4,775 shares of the biotechnology company’s stock valued at $2,588,000 after buying an additional 29 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have commented on UTHR. Morgan Stanley increased their price target on shares of United Therapeutics from $515.00 to $566.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 7th. HC Wainwright started coverage on United Therapeutics in a report on Monday, November 9th. They set a “buy” rating and a $660.00 price target for the company. Leerink Partners upped their price target on shares of United Therapeutics from $685.00 to $725.00 and gave the company an “outperform” rating in a research note on Monday, October 19th. Wells Fargo & Company upped their target price on United Therapeutics from $700.00 to $703.00 and gave the company an “overweight” rating in a research report on Thursday, November 5th. Finally, Raymond James Financial set a $720.00 price target on United Therapeutics in a research note on Wednesday, November 4th. Twelve investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, United Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $676.40.

Read Our Latest Stock Analysis on United Therapeutics

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, Director Christopher Patusky sold 1,210 shares of United Therapeutics stock in a transaction on Monday, November 9th. The shares were sold at an average price of $580.00, for a total value of $701,800.00. Following the completion of the sale, the director directly owned 2,140 shares of the company’s stock, valued at approximately $1,241,200. The trade was a 36.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Paul A. Mahon sold 8,300 shares of the stock in a transaction dated Thursday, November 5th. The stock was sold at an average price of $598.67, for a total transaction of $4,968,961.00. Following the transaction, the executive vice president directly owned 45,172 shares in the company, valued at $27,043,121.24. This trade represents a 15.52% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 403,938 shares of company stock valued at $218,025,739. 8.60% of the stock is currently owned by company insiders.

United Therapeutics Price Performance

Shares of United Therapeutics stock opened at $577.34 on Thursday. The company’s 50 day moving average price is $547.74 and its two-hundred day moving average price is $538.10. The firm has a market capitalization of $24.59 billion, a P/E ratio of 21.79, a P/E/G ratio of 3.88 and a beta of 0.49. United Therapeutics Corporation has a fifty-two week low of $455.63 and a fifty-two week high of $614.23.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last issued its quarterly earnings data on Wednesday, November 4th. The biotechnology company reported $5.71 earnings per share for the quarter, missing analysts’ consensus estimates of $6.01 by ($0.30). United Therapeutics had a return on equity of 19.18% and a net margin of 38.61%. The firm had revenue of $832.50 million for the quarter, compared to the consensus estimate of $781.14 million. During the same quarter in the prior year, the firm earned $7.16 EPS. The company’s revenue was up 4.1% on a year-over-year basis. On average, analysts expect that United Therapeutics Corporation will post 25.08 earnings per share for the current year.

United Therapeutics declared that its board has authorized a share repurchase plan on Thursday, October 22nd that allows the company to buy back $2 billion in shares. This repurchase authorization allows the biotechnology company to repurchase up to 8.3% of its shares through open market purchases. Share repurchase plans are often a sign that the company’s board believes its stock is undervalued.

About United Therapeutics

(Free Report)

United Therapeutics is a biotechnology company that develops and commercializes treatments for serious diseases, with a primary focus on pulmonary arterial hypertension (PAH). Its therapies include treprostinil products delivered by injection, inhalation, or oral tablet, marketed under brands including Remodulin, Tyvaso, and Orenitram. The company also markets Unituxin, a treatment for high-risk neuroblastoma. Founded in 1996 by Martine Rothblatt, United Therapeutics is also pursuing technologies intended to address the shortage of transplantable organs.

See Also

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR – Free Report).

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.